<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04450186</url>
  </required_header>
  <id_info>
    <org_study_id>35RC19_9750_NEUROFEEDEP</org_study_id>
    <secondary_id>2019-A02877-50</secondary_id>
    <nct_id>NCT04450186</nct_id>
  </id_info>
  <brief_title>Study Pilot - Hybrid EEG/fMRI Neurofeedback in Depressed Patients</brief_title>
  <acronym>NEUROFEEDEP</acronym>
  <official_title>Study Pilot - Hybrid EEG/fMRI Neurofeedback in Depressed Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cognitive impairment is a common residual symptom after a depressive episode and expose
      patients to a risk of relapsing or therapeutic resistance.

      Neurofeedback (using ElectroEncephaloGraphy - EEG or functional Magnetic Resonance Imaging -
      fMRI) allows patients to self-regulate their cerebral activity, which is supposedly provided
      through an intelligible and motivating feedback.

      Recent results exhibited clinical improvement in depressed patients who underwent a fMRI
      neurofeedback protocol targeting the amygdala. Furthermore, prefrontal alpha activity was
      temporally correlated to variations of the BOLD signal in the amygdala. Simultaneous fMRI/EEG
      neurofeedback is hypothesized to potentialize its antidepressant effect.

      Our objective will be to test this assumption by conducting a double-blind randomized trial,
      and to prove the superiority of bimodal fMRI/EEG neurofeedback over fMRI neurofeedback alone
      in depressed patients.

      An original visual feedback will be provided and validated beforehand by a pilot study.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EEG power in alpha band</measure>
    <time_frame>day 1</time_frame>
    <description>Measurement by an enregistrement in EEG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cerebral activation in fMRI</measure>
    <time_frame>day 1</time_frame>
    <description>Measurement by an enregistrement in fMRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technology prone behaviour</measure>
    <time_frame>day 1</time_frame>
    <description>Measurement by Locus of Control Related to Technology (LCRT) (Beier, 2004, French translation Chikhi, 2017) :
Description : Subjective 5-point Likert scale. 8 questions. Self-report.
Minimal score : 8
Maximal score: 40
Interpretation : Assessment of the affinity to technology (higher score - better handling). No cut-off.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxious personality traits</measure>
    <time_frame>day 1</time_frame>
    <description>Measurement by State Trait Anxiety Inventory (STAI - Y) (Spielberger, 1983, French translation Spielberger 1993)
Description : 4-point Likert scale. 40 questions. Self report.
Two parts : State-anxiety (20 questions) and Trait-anxiety (20 questions)
Minimal score : 20
Maximal score : 80
Interpretation : &gt; 65 - very high anxiety, 56-65 - high, 46-55 - average, 36-45 - low, &lt; 35 - very low</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mindfulness skills</measure>
    <time_frame>day 1</time_frame>
    <description>Measurement by Five Facets Mindfulness Questionnaire (FFMQ) (Baer, 2006, French translation Heeren, 2011)
Description : 5-point Likert scale. 39 questions. Self-report. Five facets : Observing, Describing, Acting with awareness, Non-judging of inner experience, Non-reactivity to inner experience
Minimal score : 39
Maximal score : 195
Interpretation : Measure of the tendency to be mindful in daily life (higher score - mindful traits). No cut-off.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>EEG/fMRI neurofeedback</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EEG/fMRI neurofeedback</intervention_name>
    <description>EEG/fMRI neurofeedback</description>
    <arm_group_label>EEG/fMRI neurofeedback</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18 to 65 years old

          2. Signature of an informed consent after being given clear and loyal oral and written
             information

        Exclusion Criteria:

        Related to the volunteer

          1. Prior experience of a neurofeedback task

             Related to the MRI

          2. Implanted cardiac pacemaker of defibrillator

          3. Brain aneurysm clip

          4. Cochlear implant

          5. Ocular on encephalic metallic foreign body

          6. Endoprothesis implanted for less than 4 weeks and ostheosynthesis device implanted for
             less than 6 weeks.

          7. Claustrophobia

             Other criteria

          8. Unstable hemodynamic status

          9. Acute respiratory failure

         10. Alteration of general state or continuous monitoring requirement

         11. Other psychiatric condition (DSM-5) such as schizophrenia, substance abuseâ€¦

         12. Neurological condition or diagnosis of dementia in medical history

         13. Undergoing treatment by benzodiazepines or anticonvulsants prescribed less than a
             month prior to inclusion

         14. Undergoing treatment influencing the blood flow prescribed less than three weeks prior
             to inclusion

         15. Protected person (adults legally protected (under judicial protection, guardianship or
             supervision), person deprived of their liberty, pregnant woman, lactating woman and
             minor)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marie Batail</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas Mevel</last_name>
    <phone>02 99 28 25 55</phone>
    <email>dri@chu-rennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Ganivet</last_name>
    <phone>02 99 28 25 55</phone>
    <email>anne.ganivet@chu-rennes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-Marie Batail</last_name>
    </contact>
    <investigator>
      <last_name>Pauline Rolland</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>June 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2020</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neurofeedback</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

